Currently viewing the tag: "AKI"
The Title says it all, Biomarkers of Kidney Disease by Charles Edelstein (and a string of noteworthy contributors) is a remarkable book collecting practically all the knowledge available on biomarkers.
For the avid reader of these pages – the book contains new groundbreaking new info – it does however give an excellent summary of the […]
Abbott takes on one of the many challenges Doctors face when dealing with AKI, new medicine helps prevent AKI stemming from cardiac surgery
http://www.renalbusiness.com/news/2012/05/abbott-pays-cash-for-aki-drug.aspx” rel=”nofollow”
Quote:
“ABBOTT PARK, Ill.—Still wheeling and dealing on the road up to its spinoff this year, the drug arm of Abbott Laboratories has snagged Action Pharma’s Phase IIb […]
Even if it does not look like the Author is crowning NGAL as the winner as the “one-and-only-biomarker” for AKI:)
One of the reasons for this is the large variation on cut-off’s used… well – that we can change easily – in a jiffy 🙂 … it’s just a matter of Alere/abbott et al using […]
Uncertainty about consequences of the recent decision by the European Patent Organisation’s (EPO) Opposition Division (OD) on the NGAL patent Is the ruling really vital for BioPorto … and in case it is not – why is it not so ? While we are still (after 8 weeks) sitting waiting for the EPO – OD’s […]
Dr. Devarajan has made a more comprehensive explanation of the nature of NGAL , the presentation is from 2010 – and since then Alere (Biosite) and Abbott has brought their test to the market.
Please note the cutoff-value mentioned (100) and bear in mind that you will find healthy individuals up to […]
Ongoing debate
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Thomas Goldberg on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Spekulant.dk on dashboard
- Muldyr on dashboard
- kasperlindvig on dashboard
